Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,878 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.21
-7.39%
5.51
Revenue and Profits:
Net Sales:
67 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.77%
0%
-30.77%
6 Months
1.5%
0%
1.5%
1 Year
-13.25%
0%
-13.25%
2 Years
46.74%
0%
46.74%
3 Years
54.33%
0%
54.33%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Devyser Diagnostics AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
29.37%
EBIT Growth (5y)
7.05%
EBIT to Interest (avg)
-31.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.53
Tax Ratio
3.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.55
EV to EBIT
-62.06
EV to EBITDA
-180.40
EV to Capital Employed
8.47
EV to Sales
9.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-13.65%
ROE (Latest)
-13.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Bearish
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
67.40
54.80
22.99%
Operating Profit (PBDIT) excl Other Income
10.90
-9.10
219.78%
Interest
3.70
0.80
362.50%
Exceptional Items
0.00
0.00
Consolidate Net Profit
1.30
-20.50
106.34%
Operating Profit Margin (Excl OI)
83.10%
-262.80%
34.59%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 22.99% vs -14.64% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 106.34% vs -540.62% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
216.90
169.30
28.12%
Operating Profit (PBDIT) excl Other Income
-40.60
-46.70
13.06%
Interest
3.50
0.80
337.50%
Exceptional Items
0.00
0.30
-100.00%
Consolidate Net Profit
-61.50
-53.60
-14.74%
Operating Profit Margin (Excl OI)
-292.80%
-333.70%
4.09%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 28.12% vs 33.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -14.74% vs -16.52% in Dec 2023
About Devyser Diagnostics AB 
Devyser Diagnostics AB
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






